The correlation analyses for IMPRESS features to residual cancer burden (RCB; Supplementary Table 7) found more significant features in HER2+ subtype (13 out of 36) than in TNBC subtype (3 out of 36), suggesting IMPRESS features may well characterize those residual tumors in HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.